
Aurinia Pharmaceuticals (AUPH) Stock Forecast & Price Target
Aurinia Pharmaceuticals (AUPH) Analyst Ratings
Bulls say
Aurinia Pharmaceuticals is projected to experience significant revenue growth, with risk-adjusted product revenues expected to increase from $243.7 million in 2025 to $932.3 million by 2033. Additionally, the company anticipates aritinercept to generate risk-adjusted revenue of $15.4 million in 2030, rising to $281.6 million by 2033, subject to a 20% probability of launch and a peak market penetration rate of 15%. Furthermore, the anticipated impact of the 2024 ACR LN guidelines is expected to catalyze further growth for LUPKYNIS starting in 2027, enhancing the overall outlook for the company's financial trajectory.
Bears say
Aurinia Pharmaceuticals has faced challenges with LUPKYNIS adoption, reflected in slow sales growth that may hinder the company's ability to achieve profitability in the near term. Additionally, the ongoing development of AUR200 comes with substantial R&D costs, which could strain financial resources and delay potential revenue generation. The overall market environment and competition in the biopharmaceutical sector may further exacerbate these financial pressures, leading to a cautious outlook on the company's stock.
This aggregate rating is based on analysts' research of Aurinia Pharmaceuticals and is not a guaranteed prediction by Public.com or investment advice.
Aurinia Pharmaceuticals (AUPH) Analyst Forecast & Price Prediction
Start investing in Aurinia Pharmaceuticals (AUPH)
Order type
Buy in
Order amount
Est. shares
0 shares